Stephen R. Plymate, M.D.
Research Interests: Dr. Plymate’s laboratory has continued work in prostate cancer over the past year. There have been three areas of funded research in his program.
1: control of prostate cancer growth and metastasis by inhibition of the type 1 IGF receptor with human monoclonal antibodies. Results in this area over the past year have shown that IGF-IR inhibition markedly enhances effects of castration by altering nuclear localization of the androgen receptor by changing AR phosphorylation sites. In collaboration with Dr. Higano, a phase 1 trial of a human IGF-IR mab is in progress at the SCCA.
2: The role of extracellualr matrix proteins, specifically laminins, in regulation of the senescent prostate epithelial phenotype and angiogenesis. This work has resulted in Dr. Plymate receiving a U54 grant in the Tumor Microenvironment Network NCI program as well as a local grant for study of laminin alpha 4 subunits.
3: Dr. Plymate has continued his collaboration with Dr. J. Wu on the innate NK immune system in prostate cancer.